---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-136785"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:22:35.073849+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company

## Summary
- OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
- Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.
- OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).
- Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.
- Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance.

## SEC filing metadata
- accession: 0001193125-24-136785
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-136785
- JSON: https://secwatch.observer/filing/0001193125-24-136785.json
- Plain text: https://secwatch.observer/filing/0001193125-24-136785.txt

## Key facts
- Executive change
  Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..
  - Action: resign
  source text: each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm
- Executive change
  Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..
  - Action: resign
  source text: each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm
- Executive change
  Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..
  - Action: resign
  source text: each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm
- Material Agreements
  OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).
  - Action: entry
  - Agreement: merger
  - Counterparty: Reneo Pharmaceuticals, Inc.
  - Effective: 2024-05-10
  source text: On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.